We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
48 hedge funds and large institutions have $83.1M invested in Crescent Biopharma in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
20,760% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $5K
481% more capital invested
Capital invested by funds: $14.3M → $83.1M (+$68.8M)
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
41% more funds holding
Funds holding: 34 → 48 (+14)
0.03% more ownership
Funds ownership: 0.49% → 0.52% (+0.03%)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Holders
48
Holders Change
+14
Holders Change %
+41.18%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
7
Reduced
12
Closed
4
Calls
$1.04M
Puts
$5K
Net Calls
+$1.04M
Net Calls Change
+$1.03M
Top Buyers
| 1 |
Millennium Management
New York
|
+$821K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$584K |
| 3 |
First Manhattan
New York
|
+$463K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$308K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$197K |
